HepaRegeniX GmbH, a Tuebingen, Germany-based clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, raised €21.5M in funding.
Backers included Wellington Partners.
The company intends to use the funds to complete its ongoing Phase Ib trial and to advance the Phase IIa clinical trial for HRX-215, its lead clinical candidate in liver regeneration.
Led by CEO Elias Papatheodorou, HepaRegeniX develops therapies to treat acute and chronic liver diseases based on discoveries of a novel cellular target and small molecules that enable the liver to regenerate rapidly. Its lead candidate, HRX-215, an orally available small molecule currently in a Phase Ib/IIa trial, selectively inhibits Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4), a master regulator of liver regeneration. Building on demonstrated safety in clinical trials, it is progressing HRX-215 to prevent post-hepatectomy liver failure, facilitate transplantation of smaller living donor liver grafts, and treat severe alcohol-associated hepatitis. Beyond liver diseases, the company is also developing HRX-233 to target kinase inhibitor treatment resistance in KRAS-driven tumors.
HepaRegeniX is backed by life science investors, including Vesalius Biocapital IV, Novo Holdings A/S, Boehringer Ingelheim Venture Fund (BIVF), Coparion, High-Tech Gründerfonds, Ascenion GmbH and Wellington Partners.
FinSMEs
15/04/2025